Compare CGC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGC | LRMR |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.2M | 455.8M |
| IPO Year | 2023 | 2014 |
| Metric | CGC | LRMR |
|---|---|---|
| Price | $0.85 | $2.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $1.95 | ★ $14.40 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,759,000.00 | N/A |
| Revenue This Year | $21.39 | N/A |
| Revenue Next Year | $8.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $2.72 |
| 52 Week High | $2.38 | $6.42 |
| Indicator | CGC | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 28.16 | 24.50 |
| Support Level | N/A | N/A |
| Resistance Level | $0.98 | $3.76 |
| Average True Range (ATR) | 0.03 | 0.19 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 14.60 | 5.24 |
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.